

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/10, 7/00, 7/01, 15/00, 15/10, 15/63, 15/86	A1	(11) International Publication Number: WO 97/43403 (43) International Publication Date: 20 November 1997 (20.11.97)
(21) International Application Number: PCT/US97/08274 (22) International Filing Date: 14 May 1997 (14.05.97) (30) Priority Data: 08/645,863 14 May 1996 (14.05.96) US (71) Applicant: BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. [US/US]; Tower Road, Ithaca, NY 14850 (US). (72) Inventors: BLISSARD, Gary, A.; 208 Eastern Heights Drive, Ithaca, NY 14850 (US). MONSMA, Scott, A.; 151 Nelson Road, Ithaca, NY 14850 (US). (74) Agent: MICHAELS, Christopher, A.; Brown, Pinnisi & Michaels, P.C., 500 M & T Bank Building, 118 North Tioga Street, Ithaca, NY 14850 (US).		(81) Designated States: CA, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: BACULOVIRUS CLONING SYSTEM (57) Abstract <p>Disclosed herein is a novel baculovirus cloning system. The new cloning system is a marker-rescue system, using an essential gene, e.g. gp64. In this system, a gene essential for viral replication, growth, or propagation in cell culture is removed from or inactivated in the viral genome. Once a null baculovirus is created, it is propagated in a host cell that expresses the essential protein or a functional homolog. For cloning into the baculovirus containing the null-mutation, the virus is used to infect wild type host cells and the same cells are transfected with a plasmid that contains the essential gene, or a functional homolog, linked to a foreign gene under the control of a selected promoter. The baculovirus is "rescued" by the rescue gene linked to the foreign gene and is able to propagate normally and express the foreign gene. The recombinant "rescued" baculovirus can be used for gene expression, biological control or presentation of a foreign protein on the surface of the virus for vaccines and antibody production.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Baculovirus Cloning System

ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

This invention was made with government support under Grant No. AI 33657,
5 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The invention pertains to the field of baculovirus cloning systems. More
10 particularly, the invention pertains to a cloning system that uses a baculovirus containing a deletion in an essential gene and the use of a stably transformed cell line to produce (and complement) production of virions that are used for marker-rescue cloning.

BACKGROUND OF THE INVENTION

15 Baculoviruses are large double stranded DNA viruses that are pathogens of insects. Infection of the host begins when insect larvae acquire the virus orally. Infection is first observed in the epithelial cells of the midgut and is followed in most cases by systemic infection. One hallmark of the baculovirus infection cycle is the production of two structurally and functionally distinct virion phenotypes. One virion phenotype, the
20 occlusion derived virus (ODV), is found within the protective occlusion bodies. Once released from the occlusion body by the alkaline pH of the gut, the ODV initiates infection of the animal by infecting epithelial cells of the midgut. A second virion phenotype, the budded virus (BV), is produced by budding from the surface of infected cells. The BV is initially produced from infected midgut epithelial cells and is essential
25 for systemic infection, mediating movement of the virus from midgut to other tissues and propagating the infection from cell to cell within the infected animal. BV are highly

infectious to tissues of the hemocoel and to cultured cells, whereas ODV appear to be less infectious in cell culture or when injected into the hemocoel. The two virion phenotypes also differ in entry mechanisms, as the BV enter cells via endocytosis, while the ODV appear to fuse directly with the plasma membrane at the cell surface.

5 The major envelope protein of the BV is the GP64 Envelope Fusion Protein (GP64 EFP, also known as GP64 or GP67), which is an extensively processed type I integral membrane glycoprotein that has been studied in some detail. Densely packed peplomers found on the surface of BV are believed to be composed of the GP64 EFP protein and these peplomers are acquired by the virion during budding. Recent studies of a soluble
10 form of GP64 EFP indicate that the native form of GP64 EFP is trimeric and thus, each peplomer is likely comprised of a single trimer of GP64 EFP. The important role of GP64 EFP in BV infectivity is demonstrated by the neutralization of BV infectivity with antibodies specific to GP64 EFP. Using syncytium formation assays and cells expressing *gp64* EFP, it was shown that the GP64 EFP protein is both necessary and sufficient for
15 low pH activated membrane fusion activity. In addition, two functional domains have been identified in GP64 EFP: an oligomerization domain necessary for trimerization and transport, and a small internal hydrophobic membrane fusion domain. Thus, functional studies of GP64 EFP show that GP64 EFP mediates membrane fusion in a pH dependent manner, consistent with an essential role for GP64 EFP during viral entry by endocytosis.

20 While indirect data on the role of GP64 EFP in the infection cycle strongly suggest that GP64 EFP is essential for infectivity of the BV, conclusive data have been lacking. No temperature sensitive mutants in the *gp64* EFP gene are known, and previous attempts to generate a helper-independent virus containing a *gp64* EFP deletion were. To demonstrate the essential nature of *gp64* EFP and to further characterize the role of GP64
25 EFP in infection, we generated a stably-transfected cell line that constitutively expresses the *gp64* EFP of OpMNPV, and used the cell line to generate a recombinant *gp64* *efp*-null AcMNPV baculovirus. We then examined the effect of the *gp64* *efp*-null mutation on viral transmission in both cell culture and insect larvae.

SUMMARY OF THE INVENTION

The present invention includes a novel baculovirus cloning system. The new cloning system is a marker-rescue system, using an essential gene. In this system, a gene essential for viral replication, growth, or propagation in cell culture is removed from the
5 viral genome. Once a null baculovirus is created it is propagated in a host cell that expresses the essential protein. For cloning into the baculovirus containing the null-mutation, the virus is used to infect wild type host cells and the same cells are transfected with a plasmid that contains the essential gene, or a functional homolog, linked to a foreign gene under the control of a selected promoter. The baculovirus is "rescued" by
10 the rescue gene linked to the foreign gene and is able to propagate normally and express the foreign gene. The recombinant "rescued" baculovirus can be used for gene expression, biological control or presentation of a foreign protein on the surface of the virus for vaccines and antibody production.

The present invention can be practiced with recombinant baculoviruses that contain
15 an insertionally inactivated or deleted *gp64 efp* gene, a gene that encodes a protein essential for viral infectivity and propagation in cell culture and in animals. To generate the virus the GP64 EFP protein can be supplied in trans, from a stably transfected cell line. Homologous recombination can be used to generate inactivated *gp64 efp* genes in the context of an otherwise wild type AcMNPV baculoviruses. For generating the stably
20 transfected cell line, a heterologous *gp64 efp* gene (derived from a different baculovirus, OpMNPV) can be selected. Viruses containing either a) an insertional inactivation of the *gp64 efp* ORF, or b) a complete deletion of the *gp64* ORF were generated by this method.

The function of this gene can be rescued by a transfection vector including a
25 "rescue" *gp64* gene. Such a transfection vector can be a plasmid containing the native AcMNPV *gp64* gene. The plasmid can be transfected into wild type Sf9 cells that are infected with a *gp64*-null baculovirus. The *gp64*-null virus is rescued when the *gp64 efp* gene is re-inserted into the viral genome by recombination and a viable baculovirus is obtained after standard virus isolation. The rescue gene can be linked to a foreign gene

under the control of an appropriate promoter such that the foreign gene and promoter are also transferred into the baculovirus genome.

This system can be used to create a *gp64*-null baculovirus for biocontrol or use as a biopesticide with infectivity limited to the insect gut. This "suicide virus" could be propagated in a cell line that expressed a functional equivalent of the GP64 protein, such the infectious null virus could be used as the biological control or biopesticide agent. The infectious null virus would not propagate in the environment, but would cause an infection in the midgut to a single insect that ingested the null baculovirus. This would limit the spread of the engineered null-baculovirus in the environment. This may be desirable if the engineered virus include a gene for a particularly toxin of concern or merely to ease concerns about releasing engineered baculoviruses.

Boublik *et al.*, teach that a fusion protein can be made with GP64 and a foreign protein (GP120) and still reach the virus surface for presentation. However, in their system the fusion protein co-expressed with normal GP64. This limits the usefulness of the system for presentation of foreign proteins to an immune system because an immune response would be eventually be generated for the GP64 and use of the system for presenting different proteins to the same animal would be of limited effect. The current system would allow the fusion protein to be expressed on all of the GP64 on the surface. Furthermore, the system could be optimized to limit the amount of GP64 expressed on the surface to the minimum amount necessary to get the fusion protein to the virus surface.

These and other advantages of the present invention will become apparent from the following drawing and detailed description.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows how the AcMNPV *gp64* *esp* gene was inactivated by inserting the bacterial *lacZ* ORF (in frame) into the *gp64* *esp* ORF after codon 131.

Figure 2 shows how Sf9 cells were stably transfected with a *gp64* gene.

Figure 3 shows how the *gp64*-null AcMNPV recombinant baculovirus was created.

Figure 4 shows how the *gp64*-null AcMNPV recombinant baculovirus is used in a marker rescue cloning system of the present invention.

5

DETAILED DESCRIPTION

The present invention involves a series of discoveries made during a study of the role of the baculovirus GP64 Envelope Fusion Protein (GP64 EFP) in the context of a viral infection. To demonstrate the essential nature of the baculovirus GP64 EFP, and to further examine the role of this protein in infection, we inactivated the *gp64* *esp* gene of Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV), and examined the biological properties of this virus *in vivo*. To provide *gp64* EFP during construction of the recombinant *gp64* EFP-null AcMNPV baculovirus, we first generated a stably transfected insect cell line (Sf9^{OP64-6}) that constitutively expressed the *gp64* EFP of Orgyia pseudotsugata MNPV (OpMNPV).

15 The AcMNPV *gp64* *esp* gene was inactivated by inserting the bacterial *lacZ* gene in frame after codon 131 of the *gp64* *esp* gene. The inactivated *gp64* gene was cloned into the AcMNPV viral genome by replacement of the wild type *gp64* *esp* locus. When propagated in the stably transfected insect cells (Sf9^{OP64-6}), budded virions produced by the recombinant AcMNPV *gp64* EFP-null virus (vAc^{64Z}) contained OpMNPV *gp64* EFP supplied by the Sf9^{OP64-6} cells. Virions propagated in Sf9^{OP64-6} cells were capable of infecting wild type Sf9 cells, and cells infected by vAc^{64Z} exhibited a blue phenotype in the presence of X-gal. Using cytochemical staining to detect vAc^{64Z} infected cells, we demonstrated that this *gp64* EFP-null virus is defective for cell to cell propagation in cell culture.

25 Although defective for cell to cell propagation, vAc^{64Z} produces occlusion bodies and infectious occlusion derived virions within the nucleus. Occlusion bodies collected from cells infected by vAc^{64Z} were infectious to midgut epithelial cells of Trichoplusia ni larvae. However, in contrast to a control virus, infection by vAc^{64Z} did not proceed into

the hemocoel. Analysis of vAc⁶⁴² occlusion bodies in a standard neonate droplet feeding assay showed no viral-induced mortality, indicating that occluded virions produced from vAc⁶⁴² could not initiate a productive (lethal) infection in neonate larvae. Thus, GP64 EFP is an essential virion structural protein that is required for propagation of the budded virus from cell to cell and for systemic infection of the host insect.

The deletion of this essential gene led to the discovery of a novel baculovirus cloning system. The new cloning system is a marker-rescue system for an essential gene. An essential gene (*gp64* is described herein as an example) is removed from, or inactivated in, the baculovirus genome and the resulting null baculovirus is propagated in a host cell that is stably transfected (or otherwise modified) to express either the native baculovirus gene or a related gene capable of complementing the null mutation in the virus. Virions produced in this manner thus contain a deleted or inactivated essential gene, but contain the essential protein supplied by the cells. These infectious virus particles are used to infect and thus efficiently deliver the null baculovirus DNA to insect cells. To use the essential gene as a selectable marker for cloning into the baculovirus genome, host cells (that do not express the essential protein) are infected with the null baculovirus particles and transfected with a plasmid that contains a functional "rescue" gene (i.e. the gene deleted or inactivated in the null baculovirus) linked to the foreign gene (both under the control of selected promoters). Viral genomic DNA's that acquire the "rescue" gene and the linked foreign gene are thus "rescued" and are able to produce infectious progeny virus particles, whereas genomic DNA's that do not acquire the "rescue" gene are defective and cannot propagate. The baculovirus is "rescued" by the rescue gene linked to the foreign gene and is able to propagate normally and express the foreign gene. The recombinant "rescued" baculovirus can be used for gene expression, biological control or presentation of a foreign protein on the surface of the virus for vaccines and antibody production.

This is a new method for creating a recombinant baculovirus that can express a foreign gene. This system has many advantages over traditional cloning systems: 1) there is a high efficiency of cloning into AcMNPV, 2) there is a high efficiency of delivery of viral genomic DNA to the insect cells, 3) no viral DNA isolation or digestion

is required, 4) a true selectable marker for cloning is provided, and 5) the *gp64* gene can be combined with a foreign gene such that a foreign protein is presented on the surface of the baculovirus in the absence of a native *gp64* gene. The cloning system of the present invention is easier to use than more traditional cloning systems. While this system can be
5 used with other essential genes, so long as there is a means for generating sufficient amounts of the null virus for the cloning system, the *gp64* gene is an excellent choice because the gene is essential for production of infectious virions.

Strategy for Initial Generation of Recombinant gp64-null Baculovirus

We generated a recombinant baculovirus that contains an insertionally inactivated
10 *gp64* *efp* gene and examined the effects of that mutation on viral infectivity, and propagation of the virus in cell culture and in animals. Previous studies of the GP64 EFP protein demonstrated that some anti-GP64 antibodies are capable of neutralizing infectivity of the virus. Because of the likelihood that inactivation of the *gp64* *efp* gene would be difficult, we chose to supply the GP64 EFP protein in trans, from a stably
15 transfected cell line, and to then use homologous recombination for generating an inactivated *gp64* *efp* gene in the context of an otherwise wild type AcMNPV baculovirus.

Because a very strong selection pressure for regenerating a *gp64* EFP+ virus may result in recombination between the virus and the *gp64* *efp* gene within the cell line, we used the following strategies:

- 20 a) For generating the stably transfected cell line, we selected a heterologous *gp64* *efp* gene (derived from a different baculovirus, OpMNPV).
- b) Recombinant vAc⁶⁴² virus stocks were screened by restriction analysis, Western blots and PCR for significant levels of any revertant virus.
- c) A lacZ marker gene was fused in-frame with the wt AcMNPV *gp64* *efp*
25 gene, and analyses of the "loss-of-function" phenotype of the recombinant virus relied on detection of the β -galactosidase marker.
- d) We generated a second vAc⁶⁴² virus with the *gp64* *efp* ORF completely deleted.

The analysis of only cells expressing the lacZ marker gene insured that we exclusively analyzed viruses carrying the inactivated *gp64 efp* gene.

Generation of Transfected Cell Lines

The first step in the above strategy involved the production of cell lines that
5 constitutively expressed the GP64 EFP protein from OpMNPV. Because previous studies using anti-GP64 EFP antibodies suggested that GP64 EFP might be an essential component of budded virions, we used a strategy in which the GP64 EFP protein was provided in trans, to complement the inactivation of the *gp64 efp* gene in the virus. To provide GP64 EFP in trans, a stably transfected cell line that constitutively expresses the
10 OpMNPV GP64 EFP protein was generated by transfection with plasmids encoding *gp64* EFP and the bacterial neomycin resistance gene, followed by selection for G418 resistance.

For production of the stably transfected cell lines (and for propagation of AcMNPV), *Spodoptera frugiperda* Sf9 cells were cultured in TNM-FH complete medium
15 containing 10% fetal bovine serum at 27° C. To express the OpMNPV *gp64* EFP, we used a *gp64* EFP expression plasmid (p64-166) that contains the OpMNPV *gp64 efp* ORF under the control of an OpMNPV *gp64 efp* early promoter construct that has been studied in detail. (See Figure 2.)

The second plasmid (pAc ie1-Neo) encodes a bacterial neomycin resistance gene
20 under the control of the AcMNPV ie1 promoter, and was constructed using the approach described by Jarvis *et al.* (1990). Transfected Sf9 cells that were resistant to G418 were selected, and isolated cell lines were established. Transfection and G418 selection were performed essentially as described previously by Jarvis *et al.* (1995). Briefly, Sf9 cells were plated at a density of 1×10^6 cells per well (34 mm diameter). The cells were
25 transfected with 2 μ g p64-166 plasmid plus 1 μ g pAc ie1-Neo using calcium phosphate precipitation. One day after transfection, the cells were replated at low density in 75 cm² flasks and maintained for 2 weeks in TNM-FH complete media containing 1 mg/ml G418 (Geneticin, GIBCO-BRL). During this period, mock-transfected Sf9 control cells died due to the G418 selection. The G418-resistant transfected cells were replated in TNM-FH

complete medium (lacking G418) at low density. Single colonies were isolated and transferred to individual wells of a 24 well plate. Isolated lines were screened for gp64 EFP expression by cell-surface staining of paraformaldehyde-fixed cells using MAb AcV5 and an alkaline phosphatase-conjugated goat-anti-mouse secondary antibody. Isolated
5 lines were also screened for GP64 EFP fusion activity using a syncytium formation assay.

Analysis of GP64 EFP Expression in Transfected Cell Lines

In addition to facilitating the construction of the recombinant virus, the use of a heterologous gp64 efp gene also allowed us to determine whether the highly conserved (but not identical) OpMNPV GP64 EFP could functionally replace the AcMNPV GP64
10 EFP protein. After constructing the OpMNPV GP64 EFP expressing cell lines, we performed several quantitative studies to compare GP64 EFP expression from AcMNPV infected cells, stably transfected cells and transiently transfected cells.

The expression of GP64 EFP from two stably transfected cell lines (Sf9^{OP64-6} and Sf9^{OP64-2}) was compared to AcMNPV infected Sf9 cells (at 24 h pi), and to transient
15 GP64 EFP expression from Sf9 cells transfected with plasmid p64-166 (at 44 h post-transfection). For these analyses, we used several quantitative techniques to determine absolute and relative levels of GP64 EFP: a) absolute levels of GP64 EFP from whole cells were determined by quantitative ECL-Western blots, b) relative surface levels of GP64 EFP were determined by CELISA, and c) variation in average surface density of
20 GP64 EFP was determined by flow cytometry.

We measured the quantities of GP64 EFP expressed on a per cell basis. A soluble secreted form of GP64 EFP (GP64 EFP^{sol}) was used to generate a standard curve for quantitative ECL analysis. The quantity of GP64 EFP detected in AcMNPV infected Sf9 cells at 24 h pi corresponds to approximately 1.3×10^6 trimers of GP64 EFP per cell.
25 The quantity of GP64 EFP detected from stably transfected line Sf9^{OP64-6} (2.5×10^5 trimers/cell) was approximately 19% of that detected from AcMNPV infected cells at 24 h pi. Total GP64 EFP levels from line Sf9^{OP64-2} were lower (1.6×10^5 trimers/cell), corresponding to approximately 12% of that detected from AcMNPV infected cells. Interestingly, transiently transfected Sf9 cells assayed at 44 h post-transfection (included

as a control) showed the highest average levels of GP64 EFP expression, approximately 3.2×10^6 trimers/cell, or 2.5 times that detected from AcMNPV infected Sf9 cells.

While the total quantity of GP64 EFP per infected cell was approximately 5 times higher than the quantity detected per Sf9^{OP64.6} cell, a further (CELISA) analysis of the average levels of GP64 EFP at the surface of these cells indicated that the level of GP64 EFP at the surface of the Sf9^{OP64.6} cells was similar to that of infected cells. Detection and quantification (by CELISA) of average relative levels of surface-localized GP64 EFP showed that the level of surface-localized GP64 EFP from Sf9^{OP64.6} cells was similar to that detected at the surface of AcMNPV infected Sf9 cells at 24 h pi, a time when virion budding is occurring. Average surface levels of GP64 EFP on Sf9^{OP64.2} cells were lower, corresponding to approximately 70% of that detected from AcMNPV infected Sf9 cells or Sf9^{OP64.6} cells. Transiently transfected Sf9 cells assayed at 44 h post-transfection expressed the highest average levels of surface GP64 EFP, corresponding to approximately 2.7 times that detected from AcMNPV infected Sf9 cells at 24 h pi.

Because GP64 EFP expression levels may vary between individual cells in a population, we also used flow cytometry to determine the degree of variation. The degree of variation (of GP64 EFP surface densities) within populations was compared between AcMNPV infected Sf9 cells at 24 h pi, stably transfected cell lines (Sf9^{OP64.6} and Sf9^{OP64.2}), and transiently transfected cells at 44 h post-transfection. Analysis of cells from each population showed that both stably transfected cell lines (Sf9^{OP64.6} and Sf9^{OP64.2}) and transiently transfected Sf9 cells contain a significantly wider variation in GP64 EFP surface densities than do AcMNPV infected Sf9 cells. A small proportion of cells in both of the stably transfected cell populations and in the transiently transfected cell population showed higher levels of surface GP64 EFP (relative fluorescence intensities of approximately 200-300) than did infected Sf9 cells (maximum fluorescence intensity of approximately 150). The flow cytometry analysis of surface GP64 EFP levels on individual cells in each population indicated that there was less cell to cell variability among AcMNPV infected cells than among Sf9^{OP64.6} cells.

Greater variability of GP64 EFP surface density appeared to be a general feature of transfected cells, since both the Sf9^{OP64.2} cell line and transiently transfected cells also

exhibited wider variations in GP64 EFP surface levels. The narrower range of GP64 EFP surface levels in infected Sf9 cells is likely due to the synchronization of GP64 EFP expression during infection, since at 24 hours postinfection, GP64 EFP expression is primarily from the late promoter. In contrast, GP64 EFP in transfected cells results from
5 constitutive expression by the early promoter and accumulation of the protein in a population of asynchronously dividing cells. In transient transfections, variable levels of GP64 EFP expression may also arise from cell to cell variations in DNA uptake during transfection.

Because cell surface levels of GP64 EFP from infected and Sf9^{OP64-6} cells were
10 similar, yet an approximately 5 fold difference was detected in the total quantity of GP64 EFP, these data suggest that no more than 20% of the total GP64 EFP protein detected from AcMNPV infected Sf9 cells (at 24 h pi) is found at the cell surface. Using this estimate of surface localization (20%) in combination with quantitative ECL data derived from whole cell measurements of GP64 EFP, we estimate that AcMNPV infected Sf9
15 cells (MOI 10, 24 h pi) contain an average surface density of 2.6×10^5 trimers of GP64 EFP per cell, at most.

Thus by several measurements, the average surface density of GP64 EFP on stably transfected Sf9^{OP64-6} cells appears to be comparable to that on AcMNPV infected Sf9 cells at 24 h pi, a time at which active budding of virions is occurring. Therefore, the level of
20 GP64 EFP expressed by Sf9^{OP64-6} cells was judged to be sufficient to complement inactivation of the *gp64 efp* gene in the AcMNPV viral genome.

Generation of a *gp64 EFP-null* AcMNPV Baculovirus

Viral DNA used for the generation of recombinant viruses was prepared from the E2 strain of AcMNPV by standard methods. For production of budded virus (BV) stocks
25 and occlusion bodies of the wild type and recombinant viruses, cells (Sf9 or Sf9^{OP64-6}) were infected at a multiplicity of infection (MOI) of 0.1 and incubated at 27° C for 5 to 7 days. Supernatants were harvested and titred by end-point dilution. The recombinant AcMNPV virus lacking GP64 expression was titred on the Sf9^{OP64-6} cells, and the wild type AcMNPV virus and recombinant virus vAc^{h2} were titred on Sf9 cells. Occlusion

bodies were purified from infected cells by sequential washing with 0.5 % SDS, 0.5 M NaCl and distilled water. For analysis of budded virion structural proteins, budded virions were isolated from viral stocks by pelleting through a 25 % sucrose pad followed by centrifugation on 25 %-60% sucrose gradients. The budded virus band was collected, 5 diluted in PBS pH 6.2, pelleted and resuspended in SDS lysis buffer for SDS-PAGE on 10% acrylamide gels.

To inactivate the *gp64 efp* gene in AcMNPV, we used insertional mutagenesis. The AcMNPV *gp64 efp* gene was inactivated by inserting the bacterial *lacZ* ORF (in frame) into the *gp64 efp* ORF after codon 131 as shown in Figure 1. Although the *lacZ* 10 ORF contains a translation termination codon, we also created a frame-shift mutation after codon 452 of *gp64 efp*, by removing a 54 bp *NcoI* restriction fragment. This frame shift resulted in a translation termination codon immediately upstream of the *gp64 EFP* transmembrane domain and insured inactivation of the *gp64 efp* gene. The *gp64-lacZ* fusion gene was then cloned into a transfer vector containing sequences flanking the *gp64* 15 *efp* locus in AcMNPV. Recombination of this transfer vector into the *gp64 efp* locus of wild type AcMNPV results in a virus wild type for all genes except *gp64 efp*.

To construct the transfer vector for allelic replacement of the *gp64 efp* locus of the AcMNPV genome, the 4718 bp *EcoRI-SmaI* fragment (corresponding to nucleotides 107,326 to 112,043 from the *EcoRI* H fragment) of AcMNPV strain E2 was cloned into 20 the pBS vector (Stratagene) to generate the plasmid pAcEcoHΔSma. This plasmid contains 2327 bp upstream of the *gp64 efp* ORF, the *gp64 efp* ORF, and 853 bp downstream of the *gp64 efp* ORF. To disrupt the AcMNPV *gp64 efp* gene by insertional mutagenesis, we generated an in-frame fusion between *gp64 EFP* and the *Escherichia coli lacZ* gene in an AcMNPV *gp64 EFP* expression plasmid pAcNru(BKH). The 25 pAcNru(BKH) expression plasmid contains an 18 bp in-frame linker encoding unique *BglII*, *KpnI* and *HindIII* restriction sites, inserted at the *BstXI* restriction site within the *gp64 efp* ORF of plasmid p166B+1 Ac Spe/*BglI*. A 3072 bp *BamHI* fragment containing the *lacZ* ORF (derived from pMC1871) was subcloned into *BglII* digested pAcNru(BKH). The resulting construct (pAcNru(*lacZ*)) contains a *gp64-lacZ* fusion after codon 131 of 30 *gp64 efp*, and the fusion gene open reading frame terminates at the end of the *lacZ*

insertion. The 3447 bp *BsmI*/*SacII* fragment of pAcNru(lacZ) (containing the lacZ cassette and the flanking portions of *gp64* *esp*) was subcloned into *BsmI*/*SacII* digested pAcEcoHΔSma, to generate plasmid pAcgp64Z. Finally, to ensure inactivation of the *gp64* *esp* gene, the downstream portion of the *gp64* *esp* ORF was truncated by digesting
 5 pAcgp64Z with *NcoI*, removing the resulting 54 bp *NcoI*-*NcoI* fragment, then blunting and religating to generate pAcgp64ZΔNco. This deletion results in a frame shift mutation and terminates the *gp64* *esp* open reading frame after codon 452, 30 codons upstream of the predicted transmembrane domain.

Figure 1 shows the construction of the *gp64*-lacZ transfer vector pAcgp64ZΔNco.
 10 Plasmid names are indicated for each construct (diagrams not to scale). Small arrows below the bottom diagram indicate the locations of primers (SEQ ID: 1 (GB 111), SEQ ID: 3 (GB 53), SEQ ID: 2 (GB 152)) used for PCR analysis. A map of the *gp64*-lacZ transfer vector pAcgp64ZΔNco is shown. The transfer vector contains 2327 bp of flanking sequences upstream of the *gp64* *esp* ORF, and 853 bp of flanking sequences
 15 downstream of the wild type *gp64* *esp* stop codon. Also indicated are the locations and orientations of genes flanking the *gp64* *esp* locus (*vcath*, *p24*, *gp16* and *pp34* (*pep*)).

Recombinant viruses were generated using standard protocols, by co-transfecting viral DNA from wild-type AcMNPV strain E2 and pAcgp64ZΔNco plasmid DNA into the *gp64* EFP expressing Sf9^{OP64.6} cells. A recombinant virus (vAc^{64Z}) was isolated from
 20 culture supernatant by plaque purification on Sf9^{OP64.6} cells, using X-gal in the agarose overlay to identify the recombinant plaques.

The structure of the *gp64* *esp* locus in vAc^{64Z} was analyzed by PCR amplification and restriction mapping. DNA was extracted from infected Sf9 cells at 24 h pi, or viral DNA was isolated from BV pelleted through a 25% sucrose cushion. For PCR analysis,
 25 the following primers homologous to the 5' and 3' ends of the *gp64* *esp* ORF were used:

SEQ ID: 1 (GB 111), 5'-GAGCTGATCGACCGTTGGGG-3'; and

SEQ ID: 2 (GB 152), 5'-CGGTTTCTGATCATACAGTACA-3'.

To verify the presence of the NcoI deletion in vAc^{64Z}, PCR amplification was performed using primers flanking the deletion site:

SEQ ID: 3 (GB 53), 5'-CCAGCGGCTGGTCGTTTATCGCCC-3'; and

SEQ ID: 2 (GB 152).

- 5 For comparisons of infection in Sf9 cells and *T. ni* larvae, a control virus (vAchsZ; kindly provided by Dr. P. Roelvink) was used. vAc^{hsZ} contains the bacterial lacZ gene (under the control of the *Drosophila* hsp70 promoter) in the p10 locus, and lacks a functional p10 gene (vAc^{hsZ} is identical to recombinant virus AcNPV/As3).

- To generate recombinant viruses defective for *gp64* EFP, transfections,
10 recombination and viral growth were carried out in the Sf9^{OP64-6} cell line. A recombinant virus (vAc^{64Z}) was isolated by plaque purification on Sf9^{OP64-6} cells, using X-gal in the plaque overlay to detect β -galactosidase expression. Although the *gp64* *efp* promoter is active in both early and late phases of infection, β -galactosidase activity was not detectable before 5-7 days pi, unless the plaque assay plates were subjected to a freeze-
15 thaw cycle to disrupt the infected cells. This result suggested that active *gp64*- β -galactosidase fusion protein was not secreted into the medium, despite the presence of the *gp64* EFP signal peptide in the GP64- β -galactosidase fusion protein.

- To confirm the location of the *gp64*-lacZ insertion in vAc^{64Z}, the *gp64* *efp* locus of the vAc^{64Z} recombinant virus was examined by PCR amplification using primers
20 complementary to the 5' and 3' ends of the *gp64* *efp* gene. As control templates for PCR, we used a plasmid containing the wild-type AcMNPV *gp64* *efp* gene (negative control), DNA from cells infected with wild type AcMNPV, or plasmid DNA of the transfer vector pAc*gp64*ZANco (positive control). Amplification from the plasmid containing the wild type *gp64* *efp* gene or AcMNPV viral DNA resulted in a 1.17 kb product, as predicted
25 from the sequence. Amplification from the pAc*gp64*ZANco transfer vector or DNA from cells infected by vAc^{64Z} resulted in a single 4.22 kb product, as predicted from allelic replacement of the *gp64* *efp* locus by the *gp64*-lacZ fusion gene. PCR analysis (using primers SEQ ID: 3 (GB 53) and SEQ ID: 2 (GB 152)) was also used to verify that the

recombinant virus vAc^{64Z} lacked the NcoI fragment deleted from the downstream region of the *gp64* *efp* ORF. The structure of the recombinant virus vAc^{64Z} was also examined by restriction enzyme digestion of viral genomic DNA. As expected, the EcoRI and BamHI restriction profile of vAc^{64Z} differed from wild type AcMNPV only in the EcoRI
5 H and BamHI G fragments, confirming replacement of the *gp64* *efp* locus. Thus, PCR analysis, restriction mapping and β -galactosidase activity indicate that the recombinant virus vAc^{64Z} contains only the *gp64-lacZ* fusion gene in the *gp64* *efp* locus, and cells infected with vAc^{64Z} express β -galactosidase activity.

To verify that the *gp64* *efp* gene was inactivated, vAc^{64Z} infected Sf9 cells were
10 examined by ECL-Western blot analysis. Cells were infected with either vAc^{64Z} or wild type AcMNPV, and cell lysates were prepared at 24 and 48 h pi. Replicate blots were probed with monoclonal antibodies specific to β -galactosidase, GP64 EFP, or P39 capsid protein. A replicate blot was also probed with a mixture of all three antibodies. Expression of β -galactosidase was detected only in cells infected with vAc^{64Z} and not in
15 cells infected with wild type AcMNPV. GP64 EFP expression was not detectable in cells infected with vAc^{64Z}. However, expression of the capsid protein P39 was detected in cells infected with either vAc^{64Z} or wild type AcMNPV.

To demonstrate the presence of OpMNPV GP64 EFP on budded virions produced by vAc^{64Z} infected Sf9^{Op64.6} cells, budded virions were purified from tissue culture
20 supernatants by sucrose gradient centrifugation and examined by Western blot analysis. As a control, budded virions were also purified from tissue culture supernatants of AcMNPV infected Sf9 cells. Replicate blots were probed with either a) a monoclonal antibody that reacts only with the OpMNPV GP64 EFP, b) a monoclonal antibody that reacts with GP64 EFPs of both OpMNPV and AcMNPV, or c) a monoclonal antibody
25 that reacts with the P39 capsid protein. GP64 EFP was detected in purified budded virions of both AcMNPV and vAc^{64Z} by monoclonal antibody AcV5 (which cross reacts with GP64 EFPs of both AcMNPV and OpMNPV), and capsid protein P39 was also detected in both budded virion preparations. Using the OpMNPV GP64 EFP-specific monoclonal antibody (OpE4A), we detected the OpMNPV GP64 EFP in purified budded

virions of vAc^{64Z}, but not in budded virions of AcMNPV. Thus vAc^{64Z} budded virions produced from Sf9^{OP64.6} cells contained the OpMNPV GP64 EFP protein.

To verify that the infection cycle proceeds normally in vAc^{64Z} infected cells, the kinetics of the infection cycle were examined by pulse-labeling of proteins. In vAc^{64Z} infected Sf9 cells, the overall pattern of protein synthesis was similar to that from Sf9 cells infected with wt AcMNPV. At 24 h pi, a labeled band of approximately 64 kD was observed in wt AcMNPV infected cells but not in vAc^{64Z} infected cells. Because 24 h pi is the time of maximal GP64 EFP synthesis in AcMNPV infected Sf9 cells, this 64 kD band is likely GP64 EFP. Comparison of the temporal progression of infection confirms progression into the late phase between 6 and 12 h pi and therefore suggests that the viral infection cycle of vAc^{64Z} is not significantly affected by the lack of GP64 EFP expression.

Because sequences flanking the *gp64 efp* genes of AcMNPV and OpMNPV are present in the recombinant virus vAc^{64Z} and in the Sf9^{OP64.6} cell line, respectively, and the two genes are highly similar, the formal possibility exists that recombination between the heterologous genes in the virus and cell line might result in replacement of the *gp64-lacZ* fusion gene with a functional (OpMNPV) *gp64 EFP* gene. In addition, selection pressure might force integration of the OpMNPV *gp64 EFP* gene at random sites within the genome. Such recombination products were not detected in DNA from the vAc^{64Z} viral stocks, using PCR amplification with primers specific for the OpMNPV *gp64 efp* gene. In control experiments, OpMNPV viral DNA was detectable with the OpMNPV specific primers when mixed with AcMNPV DNA at a molar ratio of 1 part OpMNPV to 10⁴ parts AcMNPV DNA, but was not detectable at 1:10⁵. Our inability to detect OpMNPV *gp64 efp* in vAc^{64Z} viral stocks therefore indicates that if any recombinant viruses carrying the OpMNPV *gp64 efp* gene were present, they occurred at a frequency of less than 1 in 10⁴ particles. Because the most likely recombination events that might restore the *gp64 efp* gene would also remove the *lacZ* gene, expression of the *lacZ* marker gene was used as the indicator of infection in subsequent analyses of vAc^{64Z} infectivity.

Production of infectious vAc^{64Z} budded virus from Sf9^{OP64.6} cells was on the order of 2-3 x 10⁷ infectious units/ml (determined by TCID50 on Sf9^{OP64.6} cells). The presence

of *gp64* EFP on the surface of the Sf9^{OP64-6} cells apparently did not interfere with infection, since the TCID50 titer of the wild type AcMNPV stock determined on the Sf9^{OP64-6} cells was approximately 1.3 fold higher than the titer determined on Sf9 cells. In addition to production of recombinant baculoviruses containing deletions or mutations
5 in *gp64* EFP, these stably transfected cell lines constitutively expressing *gp64* EFP will also be useful for studies of *gp64* EFP mediated membrane fusion.
gp64 *efp* is an essential baculovirus gene.

The production of infectious budded virions by vAc^{64Z} infected Sf9^{OP64-6} cells demonstrates that the OpMNPV *gp64* EFP can functionally substitute for the AcMNPV
10 *gp64* EFP in the production of budded virions. In addition, vAc^{64Z} virions (produced in Sf9^{OP64-6} cells) were infectious to Sf9 cells indicating that this aspect of host range was apparently unaffected. Thus the GP64 EFP protein from these two related baculoviruses appears to be interchangeable. Of particular importance, we demonstrate that vAc^{64Z} budded virions produced in Sf9^{OP64-6} cells are able to enter and infect Sf9 cells, but in the
15 absence of the *gp64* *efp* gene, the vAc^{64Z} virus is unable to transmit the infection to uninfected neighboring cells. Thus *gp64* *efp* is an essential baculovirus gene, and the GP64 EFP protein is required for the cell to cell transmission of the infection. Studies are now in progress to identify the cause of the defect in viral transmission. Preliminary studies suggest that virion budding is defective in the absence of GP64 EFP.

20 In previous studies, the transmission of virus from the midgut to hemocoel has been studied using marker genes to follow the progression of tissues infected. Virions have been observed budding from the basal side of the midgut epithelial cells and virion budding is believed to serve as the primary mode of viral movement from midgut epithelium to hemocoel. Hemocytes, cells of the tracheal system, and basal lamina
25 associated muscle and tracheal cells have been proposed as the primary cells infected after the first round of replication in midgut epithelial cells. It has also recently been suggested that the tracheal system may serve as a route for budded virus transmission across the basal lamina of the midgut epithelium to other tissues within the hemocoel.

We examined the role of GP64 EFP during infection in the animal by feeding
30 occlusion bodies prepared from vAc^{64Z} infected cells to either neonate or early 4th instar

T. ni larvae. Using whole mount histological staining of 4th instar T. ni larvae to detect infection, we found that the vAc^{64Z} occlusion derived virions were capable of infecting cells of the midgut epithelium, but infection by vAc^{64Z} did not move beyond the midgut. The ability of vAc^{64Z} to produce infectious occluded virions in the absence of GP64 EFP expression is consistent with previous studies that found no detectable GP64 EFP protein associated with the occluded virus, and clearly demonstrates the virion phenotype specificity of the GP64 EFP protein.

As perhaps the most sensitive indicator of systemic propagation of viral infection, we examined mortality in neonate larvae fed occlusion bodies of vAc^{64Z}. At doses of up to 100x the LD65 of AcMNPV, the vAc^{64Z} virus was non-lethal to T. ni neonates. The lack of vAc^{64Z} induced mortality in T. ni neonate larvae thus confirms the observations in tissues of whole 4th instar larvae, and demonstrates that the inability of the vAc^{64Z} virus to escape from the midgut epithelium results in a non-lethal phenotype in the animal. These results therefore demonstrate an absolute requirement for GP64 EFP in the progression of the infection from the midgut epithelium to the systemic form of the disease in tissues of the hemocoel.

The deletion of this essential gene led to the development and discovery of a novel baculovirus cloning system and a novel strategy for biopesticide delivery. As stated above, the new cloning system is a marker-rescue system for an essential gene, and in this example GP64 EFP was selected. Once the *gp64*-null baculovirus is created, (e.g. *gp64*-null AcMNPV) it can be propagated in a transfected cell line expressing a *gp64* gene from the same or a different baculovirus (e.g. OpMNPV). This provides an infectious virus that can be used to infect a cell line, but will not lead to production of new virus particles in a wild type cell line unless *gp64* expression is "rescued". To rescue *gp64*, *gp64*-null virus infected wild type cells are transfected with a plasmid that contains a *gp64* gene construct and the virus is rescued by recombination. For cloning foreign genes, the rescue of *gp64* expression is linked to a foreign gene. This can be accomplished by linking a foreign gene (under control of an appropriate promoter) to the *gp64* gene construct on the same plasmid and providing sequences for recombination such that recombination occurs at sites flanking the two genes or otherwise results in insertion of

both genes into the viral genome. The baculovirus is "rescued" by the rescue gene linked to the foreign gene, thus resulting in a baculovirus that has acquired the foreign gene and now is able to propagate normally and express the foreign gene. The recombinant "rescued" baculovirus can be used for gene expression, biological control as a
5 biopesticide or for the presentation of a foreign protein on the surface of the virus for vaccines and antibody production.

This is a new method for creating a recombinant baculovirus that can express a foreign gene. This system eliminates the isolation and use of viral genomic DNA for baculovirus cloning. Problems and difficulties associated with the use of viral genomic
10 DNA include: linearization with restriction enzymes, quality control testing of digestion and DNA quality (for integrity and transfection), and concerns with storage, nucleases, etc.. A decrease of 50-80 % in the commercial cost of producing the necessary reagents for a baculovirus cloning system can be realized by implementation of this marker-rescue cloning system. Furthermore, commercial suppliers of cloning systems can provide kits
15 with the cell lines, plasmids and baculovirus necessary for the cloning system in one package. While this was possible before, the present system will need the recombinant cell line expressing the heterologous protein for production of infectious null baculovirus to be "rescued". Therefore, the consumer will need to continue to purchase the infectious null baculovirus from the company, because without the infectious null baculovirus cannot
20 be produced recombinant cell line.

Once optimized, the efficiency of cloning into baculovirus genomes will be improved with the cloning system of the present invention. The efficiency of virion entry into host cells is far more efficient than transfection of the isolated circular or linear DNA genome of baculovirus which range from approximately 90-180 kbp. The virus is
25 evolutionarily designed to efficiently deliver DNA to the nucleus of its host cell, whereas artificial transfection of such large DNA (especially linearized DNA) is extremely inefficient. Because engineering some baculovirus genomes is problematic due to the large size of the genome (up to 180 kbp), this system eliminates the problems of poor transfection efficiencies and the need to repeatedly isolate and linearize genomic DNA.

This system can be used with other essential genes, so long as there is a means for generating sufficient amounts of the null virus for the cloning system. The *gp64* gene is an excellent choice because the gene is essential for production of infectious virions.

Other genes that may prove similarly useful for generating viruses with null-mutations and similar rescue strategies include other genes that are essential or important for viral structure, replication or propagation in cell culture. Such genes may include capsid protein genes (*vp 39*, *p80/87*, *p24* or *p78/83*), other as yet uncharacterized envelope protein genes from the budded form of the virus or essential regulatory genes such as *ie-1*, *ie-N*, (*ie-2*), and *lef* genes. Other mutations that render the expression of these genes may be possible. For example deletion or inactivation of promoters or other control elements for essential genes could accomplish the same purpose.

This system can be used to develop cloning systems for an number of baculoviruses. The *gp64* gene has been isolated and sequenced in a number of baculoviruses. For example, cloning systems could be created from the teachings herein and information available in the literature for the following systems: *Orgyia pseudotsugata* MNPV (OpMNPV), *Trichoplusia ni* SNPV (TnSNPV), *Lymantria dispar* MNPV (LdMNPV), *Choristoneura fumiferana* MNPV (CfMNPV), *Bombyx mori* NPV (BmNPV), and other baculoviruses.

Accordingly, it is to be understood that the embodiments of the invention herein described are merely illustrative of the application of the principles of the invention. Reference herein to details of the illustrated embodiments are not intended to limit the scope of the claims, which themselves recite those features regarded as essential to the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: Blissard, Gary W
Monsama, Scott A

10

(ii) TITLE OF INVENTION: Baculovirus Cloning System

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Barnard, Brown & Michaels
(B) STREET: 306 East State Street; Suite 220
(C) CITY: Ithaca
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 14850

20

(v) COMPUTER READABLE FORM:

25

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

30

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

35

(A) NAME: Michaels, Christopher A
(B) REGISTRATION NUMBER: 34390
(C) REFERENCE/DOCKET NUMBER: BTI-31

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 607-273-1711

22

(B) TELEFAX: 607-273-2609

(2) INFORMATION FOR SEQ ID NO:1:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PCR primer"

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20 GAGCTGATCG ACCGTTGGGG

20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "PCR primer"

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGTTTCTGA TCATACAGTA CA

22

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "PCR primer"

15

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCAGCGGCTG GTCGTTTATC GCCC

24

What is claimed is:

1. A method of cloning DNA into a baculovirus comprising the following steps:

5 a) selecting infectious null-baculovirus particles that include a null mutation such that said infectious null-baculovirus particles lack a functional essential gene for production or propagation of infectious virus particles in wild type host cells, but can be propagated in modified host cells expressing a gene that allows production of infectious virus particles;

10 b) selecting a rescue transfection vector that includes a rescue DNA that restores function of said functional essential gene lacking in said null-baculovirus;

c) infecting host cells with said infectious null-baculovirus particles and transfecting with said rescue transfection vector;

15 d) culturing said transfected host cells to select for recombinant baculovirus particles that express said rescue DNA; and

e) harvesting said recombinant baculovirus particles that express said rescue DNA.

20 2. The method of claim 1 wherein said rescue DNA is linked to a foreign gene under the control of an appropriate promoter such that said foreign gene is expressed when said harvested recombinant baculovirus particles are used to infect host cells.

3. The method of claim 1 wherein said essential gene is *gp64* and said modified host cell expresses a *gp64* gene.

25 4. An improved method of cloning DNA into a baculovirus by providing said DNA to be cloned in said baculovirus within a host cell and providing viral genomic DNA for said baculovirus with said host cell, wherein said improvement comprises:

5 a) providing said viral genomic DNA to said host cell with an infectious null-baculovirus particle that includes a mutation such that said infectious null-baculovirus particle lacks a functional essential gene for production of an infectious virus particle in wild type host cells, but can be propagated in modified host cells expressing a gene that allows production of infectious virus particles; and

b) said DNA to be cloned into said baculovirus includes a rescue DNA that restores function of said functional essential gene lacking in said null-baculovirus.

10 5. The method of claim 4 wherein said rescue DNA is linked to a foreign gene under the control of an appropriate promoter such that said foreign gene is expressed when said harvested recombinant baculovirus particles are used to infect host cells.

6. The method of claim 4 wherein said essential gene is *gp64* and said modified host cell expresses a *gp64* gene.

15 7. An infectious null-baculovirus particle that includes a mutation such that said infectious baculovirus particle lacks a functional essential gene for production of an infectious virus particle in wild type host cells, but can be propagated in modified host cells expressing a gene that allows production of infectious virus particles.

20 8. The baculovirus of claim 7 wherein said essential gene is *gp64* and said modified host cell expresses a *gp64* gene.


25 9. A modified host cell that expresses a gene that allows production of infectious virus particles when infected with an infectious null-baculovirus particle that includes a mutation such that said infectious baculovirus particle lacks a functional essential gene for production of infectious virus particles in wild type host cells.

10. The cell of claim 9 wherein said functional essential gene lacking in said baculovirus particle is a *gp64* gene and said modified host cell expresses a *gp64* gene.


11. A transfer vector that includes a rescue DNA that restores permanent function of a functional essential gene that has been inactivated or deleted in a baculovirus such that said baculovirus can not produce infectious virus particles in wild type host cells, but can be propagated in modified host cells expressing a gene that allows
5 production of infectious virus particles, when said baculovirus and said transfer vector are used to co-transfect a host cell and produce recombinant baculovirus particles.
12. The transfer vector of claim 11 wherein said rescue DNA is linked to a foreign gene under the control of an appropriate promoter such that said foreign gene is
10 expressed when said recombinant baculovirus particles are used to infect host cells.
13. The transfer vector of claim 12 wherein said rescue DNA is DNA that restores function of a *gp64* gene.

1/4


Figure 1



2/4


Figure 2

3/4

Figure 3

4/4

Figure 4



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/08274**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : 435/5, 6, 172.3, 235.1, 320.1, 348

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 6, 172.3, 235.1, 320.1, 348

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Biosis, Biotech, Medline

Search terms: baculovirus, gp64, null baculovirus, essential gene, rescue vector

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,162,222 A (GUARINO et al.) 10 November 1992, columns 3-4.	1-13
A	JARVIS, D.L. Effects of Baculovirus Infection on IE1-Mediated Foreign Gene Expression in Stably Transformed Insect Cells. Journal of Virology. May 1993, Vol. 67, No. 5, pages 2583-2591, especially pages 2589-2590.	1-13
A	JARVIS et al. Use of Early Baculovirus Promoters for Continuous Expression and Efficient Processing of Foreign Gene Products in Stably Transformed Lepidopteran Cells. BIO/TECHNOLOGY. October 1990, Vol. 8, pages 950-955, especially pages 953-954.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* G*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

18 JULY 1997

Date of mailing of the international search report

22 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

David Guzo

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/08274

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12N 5/10, 7/00, 7/01, 15/00, 15/10, 15/63, 15/86